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Obese or overweight people exceed one-third of the global population and obesity along with 
diabetes mellitus consist basic components of metabolic syndrome, both of which are known 
cardio-cerebrovascular risk factors with detrimental consequences. These data signify the 
pandemic character of obesity and the necessity for effective treatments. Substantial advances 
have been accomplished in preclinical research of obesity by using animal models, which mimic 
the human disease. In particular, rodent models have been widely used for many decades with 
success for the elucidation of the pathophysiology of obesity, since they share physiological 
and genetic components with humans and appear advantageous in their husbandry. The most 
representative rodents include the laboratory mouse and rat. Within this review, we attempted 
to consolidate the most widely used mice and rat models of obesity and highlight their strengths 
as well as weaknesses in a critical way. Our aim was to bridge the gap between laboratory 
facilities and patient’s bed and help the researcher find the appropriate animal model for his/her 
obesity research. This tactful selection of the appropriate model of obesity may offer more 
translational the derived results.. In this regard, we included, the main diet induced models, the 







Obesity is characterized by increased fat mass in body and caused by a prolonged 
misbalance of energy intake and energy expenditure 1–3. The expansion of adipose tissue is the 
final result of both environmental factors (including hypercaloric food intake and physical 
inactivity) and genetic predisposition 4. Hereditability is estimated to range from 40 – 70% 5.  
Obesity consists a global substantial clinical and economical burden reaching nowadays 
pandemic proportions, since about 1.5 billion adults are overweight and, among them, it is 
estimated that 200 million men and 300 million women are obese 6. Obesity has also an 
increasing prevalence in childhood, adolescence and women of reproductive age, both in the 
developed and developing countries 7,8.  
Obesity related to metabolic syndrome (MetS) represents a principal risk factor for 
diseases and disability 9; it serves as substrate and basic component of MetS and hosts many 
comorbidities including hypertension, hyperlipidemia, diabetes mellitus type 2 (T2DM), 
chronic kidney disease, cardiovascular disease (CVD), osteoarthritis, malignancies and 
nonalcoholic fatty liver disease (NAFLD) 10,11. A subcategory of obesity without MetS, referred 
to as metabolically healthy obesity has yielded contradictory estimates of association with CVD 
12.  
A number of animal models have been used to study the obese response to various forms of 
disease. In this regard, preclinical animal models have been used successfully over many 
decades for the purposes of basic research, so as the complex pathogenetic mechanisms of 
diseases are elucidated. Two main types of obese animal models are used: monogenic (mutation 
linked to only one gene) and polygenic [diet-induced obesity (DIO)] 13,14.  
Generally, monogenic models have commonly used a mutation in the leptin pathway, 
though it has been revealed that the single manipulation of almost 250 different genes in mice 
can induce obesity 3. In DIO models, obesity is often produced by feeding animals a 
 
 
hypercaloric diet. Two frequent variants include the high-fat diet (HFD) 15, which induces 
obesity owing to its high energy density, and the cafeteria diet, which stimulates hyperphagia 
(and consequent obesity) owing to its palatability 3. Other less common models of obesity 
include those produced by chemical or surgical approaches 3.  
A wide variety of animal models are reported in numerous publications, from worm 
Caenorhabditis elegans and fly Drosophila melanogaster to Zebrafish and mammals (non-
human primates or not). Rodents have dominated for a long time in biomedical research and 
are represented mainly by the laboratory mouse (Mus musculus) and rat (Rattus norvegicus 
domesticus) 16. Other species being used include pigs, sheep and even unusual ones including 
seals and bats 3. Mice and rats are regarded as the ideal animal models for obesity research and 
preclinical research generally and are preferred over other animal models, since they share 
many anatomic, physiologic as well as genetic similarities with human 17. Noteworthy, they 
have along with human about 30,000 genes, 95% of them are common in these three species 17. 
Furthermore, rodents are characterized by a small body size and rapid reproduction, which 
constitutes their husbandry easy and inexpensive.  
The contribution of mice and rats to obesity and diabetes research is important. We 
hereby demonstrate some representative examples. The revolutionary discovery of adipocyte-
derived cytokine hormone leptin 18 and its receptor 19,20 was a consequence of characterization 
of the underlying genetic defect in mutant mice (both db/db and ob/ob); the ob/ob mouse, one 
of the monogenic animals most used in the study of obesity and MetS, does not produce leptin, 
but is still sensitive to it 21. Likewise, the substantial elucidation of the role of melanocyte 
stimulating hormone and its associated agouti-related peptide 22,23 signaling via the 
melanocortin-4 receptor 24,25 was also performed in mice. Of note, the aforementioned genes as 
well as the one of leptin, are all known etiologies for monogenic obesity of human 2. 
Furthermore, the discovery of another novel central key-player regulator of energy balance, 
ghrelin, took place in rats 26. 
 
 
In this review, we summarize the main rodent models of obesity, highlighting 
respectively the advantages as well as limitations characterizing each model. We followed an 
etiologic classification, distinguishing also between the species and genetic substrate (Figure 
1); obesity models can be developed easily in a chemical/mechanical way, by modifying the 
diet (DIO), or by modifying genome (the so-called genetically engineered models, GEM). A 
synopsis of all discussed models can be found in enclosed Table 1. We referred to some models, 
whose use is declining, mainly for historical reasons. Nonetheless, an extensive description of 
all ever-used rodent models exceeds the scope of the present review.  
 
Diet-induced (caloric excess) rodent models of obesity 
DIO belongs to the traditional and widely used rodent models mimicking human obesity 
27–29. Animals are given typically high caloric food (rich in sugar and/or fats) ad libidum and 
the progression to obesity and diabetes development is slow and recapitulates in a satisfactory 
manner the corresponding human pathology, in which fat is slowly accumulated, mainly due to 
excess of energy and insufficient expenditure 28,29. Although there is a lack of standardized, 
classic DIO, many labs use defined HFD (see also Table 2), which contain 45-60% calories 
from animal source fat (lard) 27,29, the latter having a more pronounced effect on insulin 
resistance (IR) and adiposity than fat of vegetable origin 30. Impaired insulin tolerance can be 
seen as early as one week after the start of diet and weight gain from the second to forth week, 
whereas a peak of the body weight can be obtained about 16-20 weeks from the beginning of 
HFD. Mice weigh 20-30% more than those fed on a standardized balanced diet (controls) 27. 
Nevertheless, studies with DIO are often more expensive and as mentioned time consuming 
and there is also a plethora of additional factors, which might limit the interpretation of results 
28,29. A representative paradigm is the varying susceptibility among different murine strains, 
due to particularities of their genetic substrate. C57BL/6J, derived from 
 
 
the same parental C57BL/6 strain, is a typical mouse strain being used for obesity and IR 
research. Other strains, like A/J and SWR/J are more resistant, thereby less appropriate for 
obesity and diabetes studies. Sprague-Dawley and Wistar rats, typically used as DIO/Mets 31, 
acquire this disorder more easily, signifying that the genetic basis is essential in body weight 
gain 32. Regarding the latter polygenic animal strain, it has also been used for studies of DIO 
demonstrating an increase in body weight 33, though the results on changes in insulinemia are 
conflicting 34,35. Remarkably, the female Wistar rat model has also been introduced as a DIO 
model during pregnancy, as a gestational obesity model and as a model for evaluation of 
offsprings born by obese mothers. The usage of hypercaloric diet during the gestational and 
lactation periods of Wistar rats appears to modify the obesity phenotype in the obese mothers 
offspring, indicating the significance of maternal nutrition 33.  
Another parameter, which should be considered upon planning the protocol of an 
experiment, is the gender selection of the rodents. It is known that male mice develop obesity 
more quickly and to a greater extent than the female ones. This sex preference affects also the 
accompanying IR and diabetes onset 28.  
Nonetheless, it should be emphasized that rodents as model for the study of pancreatic 
islets are less appropriate, as their anatomic architecture deviates 28. The translational value of 
this murine particularity regarding sex reflects partially to human patients with men being more 
prone to diabetes onset, but women more prone to obesity.  
This phenotypic sexual difference can be interpreted, due to different gonadal hormones 
(estradiol/progesterone versus testosterone), which impacts the topographical distribution of fat 
28. Particularly, it is known that downregulation of  the tumor suppressor phosphatase and tensin 
homolog (PTEN) leads to retention of insulin sensitivity with accompanied higher adiposity in 
women compared to men36. Additionally, AEBP1 is a transcriptional repressor, which serves 
as regulator of PTEN expression in a negative way. It has been found to play a key-role  in 
modulation of adiposity via fat-cell proliferation and is implicated in a gender-specific 
 
 
susceptibility to diet-induced obesity by the estrogen signaling pathway37. Moreover, HFD-
fed AEBP1 females exhibit over-induction of AEBP1 and a noticeable reduction of PTEN level 
with concomitant hyper-activation of the survival signal in adipose tissue37. 
An additional parameter, which has to be taken into account for murine experiments, is 
the age. For instance, C57BL/6J strain reaches a maximal body weight at nine months after 
birth and and C57BL/6J mice 22 months old appear reduced lean mass and increased fat mass 
compared with young 3-month-old. This simulates analogously the observed phenomenon in 
humans, where a fat redistribution takes place at 30 years of life and a peak of body weight is 
anticipated for both genders at about 55 years. Furthermore, epigenetic inheritance of diet-
induced obesity is well described and plays an important role in performed experiments 28. 
Interestingly, many studies have demonstrated the effects of an in utero HFD on offspring 
weight, regardless of the animal model; these observations have been replicated in human MetS 
38–40. The exact molecular mechanism is not well defined, although DNA methylation and 
histone modifications seem to play a key role 38.  
The modern diet in humans is frequently comprised of high level of fats and 
carbohydrates. Rodent relative data are based on these diets, though there is variation in the 
quantity of components introduced and in their source, which might alter the animals’ 
phenotype 32. It is worthy, however, that, although many rodent diets are close enough in 
composition to the human ones of modern western societies, the regime of feeding ad libidum 
with the identical meal throughout the light dark-cycle (circadian rhythm), more or less for 
many weeks is monotonous and let the animals without choice. Such a simplified approach 
might be attractive for the performers of an experiment, although does not reflect satisfactory 
the habits of human in the real world, where a wide variety of meals is available 29. In order to 
cope with this problem, several custom diets have been introduced, the most common of which 




Cafeteria (supermarket) diets 
‘Cafeteria’ diets (CAF-Ds) provide to animals a mixture of savory and sweet, high fat 
and/or high sugar solid nutrition emanating from human larder. They appeal as attractive 
models of modern human obesogenic diets 29. CAF-D-induced obesity is the result of 
hyperphagia, which is only partially compensated by increased energy expenditure. This 
phenomenon is feasible particular in diet-induced thermogenesis, once sympathetic activation 
of brown fat takes place. Hyperphagia of cafeteria diets is explained by increase of both meal 
portion and meal frequency. This contrasts with overeating of palatable diets with no choice of 
food, which mainly influences meal size 41. Nevertheless, the aforementioned options are used 
less frequently than diets of a single-source fat, due to the existing of logistical constraints and 
sceptism over the heterogeneity and lacking of standardization, making calculations of energy 
and macronutrient intake rather difficult 29. Due to these concerns, CAF-D regime has been 
lately revised. The so-called “junk food” diet offers a choice of snacks / processed food apart 
from a lard/chow mix and has been introduced to feed adult Wistar rats (both genders) 42, to rat 
dams before being mated and until their offspring are weaned, and to their offspring as well 43. 
This regime resulted in increases in body fat mass in all groups. Moreover, perinatal exposure 
of offspring to high-sugar and high-fat diets increased their intake of lipids the time of weaning 
29. Of note, CAF-D-related obesity seems to induce an increased oxidative damage in white 
adipose tissue affecting tissue homeostasis and oxidative stress (OS) drives activation of 
inflammatory kinases that can disturb insulin signaling resulting in glucose intolerance and 
diabetes 44. Moreover, the noticeable microbiota dysbiosis observed in CAF-fed rats might 
result from the presence of several additives of the CAF diet, or even a absence of essential 
vitamins and minerals 45. The gut microbiota dysbiosis-derived products provoke low-grade 
inflammatory activation of tissue-resident macrophages and contribute to metabolic and 
degenerative disorders, including obesity diabetes and MetS 46.   
 
 
Regarding the mentioned OS, interestingly, recent data indicate that the therapeutic 
effects of resveratrol against hepatic steatosis of HFD obese male C57BL/6 mice are attributed 
to the decrease of hepatic OS, inflammation and free fatty acid uptake 47. Likewise, Cordyceps 
militaris with its anti-obesity actions can be inhibited endoplasmic reticulum (ER) stress and 
ER stress-induced apoptosis in the hepatic steatosis of this HFD-induced obesity model 48. 
 
Fat or sugar choice diets 
This sort of diets is a simplification of a CAF-D, which aims at overcoming the 
previously described limitations 29. For instance, la Fleur et al. proposed a relevant rat model 
49, in which the free-choice of  “high-fat, high-sugar” diet allows rodents to choose between a 
dish of saturated fat, a bottle of 30% sucrose, and standard chow. Animals were persistently 
hyperphagic (eating to excess) and became obese compared to those fed a no-choice pre-mix 
off at, sugar and chow, which induced only transient overeating. Increased caloric intake in the 
free-choice group was the result of an increase in the number of meals due to drinking of sugary 
liquid without any modification of meal size 49. This obesity model is attractive due to inducing 
the desired overconsumption of calories by offering a free choice of diet depending on appetite 
of animals 29.  
Sugar based diets, namely the ones containing simple carbohydrates can be divided to 
fructose-enriched (fruit monosaccharide) and sucrose-enriched (the common table sugar, 
containing one molecule of monosaccharide glucose and one of fructose) 31. Fructose high 
levels in mice mimic the human diet and, when associated with high fat content, promote weight 
gain, abdominal fat, hyperglycemia and hyperinsulinemia 50. Fructose appears to be important 
in obesity and MetS development, because this sugar induces not only IR, but also leptin 
resistance, thereby leading to weight gain 37,51,52. Fat based diets might use either as source 






There are different models of meal feeding, depending on the methodology used in each 
study and its purpose. Their role in obesity studies remains limited, as specific feeding patterns 
are involved and resulted obesity and adiposity are affected by multiple variances. On the other 
hand, senses before and after the meal and the central nervous system (CNS) reactions have 
been examined by these techniques, using the advantage of conventionalizing the normal 
physiological status around the meal 53. The most recognizable example of that method is the 
ad libitum model, which simulates to the natural situation of rodents, offering to the subjects an 
unlimited access to a specific HFD. More functional and commonly used alternatives include 
predetermined periods of food provisioning; disposal of the meals at specific intervals and for 
limited time along day 29. Recent data indicate that time-restricted feeding entrains diurnal 
rhythmicity in vagal afferent mechanosensitivity in both lean and HFD-induced obese mice and 
inhibits the loss of rhythmicity in HFD-induced obesity, thereby having implications for the 
development of relative therapeutic strategies against obesity 54.  
 
Binge-type feeding 
Based on the principle that eating requirement is the resultant of daily habits, social 
environment, or convenience, this method is often used to study and control eating behavior, 
rather than obesity and metabolic disorders 42,55. The mainstay of binge-type feeding is the 
flavorful meal  provided in scheduled intervals simultaneously with a basic diet. This 
“rewarding” pattern could result in obesity in models with greater alterations in limbic and 
motivational circuits in response to palatable food 42,55,56.  
The aforementioned possibility led to proposition of a classification based on rats’ 
susceptibility to binge-type diet. Binge eating prone (BEP) rodents gorge more than twice of 
 
 
the palatable food instead to binge eating resistant (BER) rats. Apparently, the resulted obesity 
is more common to the first subgroup 57.  
From a clinical point of view, excessive consumption of highly-palatable and energy-dense 
foods is commonly observed in patients with eating disorders  (binge eating disorder [BED] 
and bulimia nervosa [BN]) and in some obese patients 58; binge-eating behavior is a main 
symptom in several eating pathologies but the neurobiological triggering factors of these 
disorders remain elusive 59.   
 
 
Impact of maternal diet on offspring  
Maternal diet effect on offspring remains a challenging issue in obesity and metabolic 
disorders. Brain programming, including hypothalamus development, is known as a key factor 
implicated in appetite regulation and energy homeostasis and follows common pathways among 
mammals 60. Nevertheless, postpartum hypothalamic maturation in rodents provides an 
important advantage to study the impact of maternal feeding to the hormonal stimulation and 
neuroregulation 61. The role of hormones, such as leptin and ghrelin, in hypothalamus formation 
could illuminate the importance of maternal diet and broaden the treatment prospects 62,63. In a 
recent meta-analysis, Ribaroff et al. included 171 animal studies of maternal diet models, 
underlying its impact to the offspring bodyweight and the overall metabolic profile, and 
suggesting the high maternal carbohydrate consumption as a possible causative factor 64. 
Moreover, recent evidence, by using the above mentioned C57BL/6 mouse model, indicates an 
augmented vulnerability of male offspring to maternal obesity-produced alterations in 
chromatin remodeling processes that regulate gene expression in the developing hippocampus, 
thereby contributing to our knowledge of how early life nutrition affects the brain epigenome 
offspring; in utero exposure to maternal HFD-induced obesity modifies oxytocin receptor 
(Oxtr) gene expression and histone binding at the Oxtr promoter in offspring hippocampus in a 
 
 
sexually dimorphic manner; and in response to HFD, Oxtr transcription augmented and 
H3K9Ac (an active histone mark) binding was enriched at the Oxtr promoter in hippocampus 
male offspring  65.  
 
In conclusion, DIO models seem to be close to the mechanisms that induce obesity and 
MetS in humans 32; these models mimic human obesity, and thus would be used for preclinical 
testing of the role of diet, etiology, pathophysiology and therapeutic interventions. 
Nevertheless, the results of the studies are inconsistent, mostly in relation to the diet 
compositions and the type of model used 32,66. Diverse strains of animals exhibit variable 
responses to these diets, with certain being prone and others being more resistant to obesity 
development 41. Because of this and the difficulty of long-term feeding with a certain diet, 
morbid obesity is not easy to replicate in DIO models. 
 
Chemical (pharmacological) models of obesity 
These models were originally proposed for the study of type 1 diabetes mellitus 
(T1DM). Well described diabetogenic agents, which are structural analogues of glucose include 
alloxan and streptozotocin and have been used for the selective destruction of pancreatic β-cells 
27,28,67. For induction of obese phenotype, however, a combination with a HFD/HSD is 
mandatory.  Pathogenetically, the intracellular entry is mediated via glucose transporter type 2 
(GLUT-2) 27,68. GLUT-2 is however, also expressed in kidney and liver, thus the administration 
of the above substances is nephrotoxic and hepatotoxic or even tumorigenic 27,28.  Induction of 
diabetes is mediated by selective necrosis of pro-beta islet cells, which are the insulin-secretory 
pancreatic cells27. Alloxan leads to beta-cell dysfunction and death by inhibiting glucokinase, 
with induces the production of reactive oxygen species27. Streptozotocin mediates 
mechanistically its action by alkylating or breaking DNA strands, which has as consequence 
 
 
the increase in the activity of poly-ADP-ribose synthetase, finally resulting in energy 
deprivation and cellular death69.  
 
Systemic toxicity of both streptozotocin and alloxan are typically seen within the first two 
weeks after diabetes induction. The latter displays a particularly narrow window of safety 
between the diabetogenic and lethal dose and deaths are often a result of diabetic ketoacidosis 
and/or renal or hepatic failure70. Alloxan nephrotoxicity especially is a consequence of the 
lipophilic derivatives after systemic administration and can be so severe that it leads to fatal 
renal failure in the animals even before diabetes can develop71. Likewise, the cell toxicity of 
streptozotocin is not limited to beta cells, but also induces direct acute damage to the kidneys 
72 as well as the liver and intestine73. 
 
 
Streptozotocin is generally preferred over alloxan, as it has a better profile, i.e., more 
stability and less toxicity28. A complete depletion of all β-cells of pancreas mimics T1DM, 
which is inappropriate for the study of obesity or MetS. Nevertheless, a partial destruction of 
some β-cells by inoculating low doses of streptozotocin can resemble human T2DM and obesity 
when a special aforementioned “junk” diet is combined. A single or even multiple shot(s) of 25 
– 70 mg/kg are given depending on the customized protocol (in which the age of rodent and the 
species-strain are primarily considered) and preferably a high fat/“western” diet is added, so as 
the slow progression of T2DM with obesity can be achieved 28,68.  
To the chemical models of obesity belongs also the so-called aurothioglucose-induced 
hypothalamic obesity although there are limitations, which constrain its usage69. 
Aurothiglucose, also known as goldthioglucose (GTG), can be administered intraperitoneally 
 
 
for the introduction of diabetes and obesity in a dosage 150-350mg/kg body weight. Onset of 
the desired phenotype is slow and may take up to 20 weeks after injection. Pathogenetically, 
the substance reaches neural cells of ventromedial hypothalamus and induces necrosis, which 
leads to hyperphagia associated obesity. Specifically, GTG induces an region of necrosis of 
ventromedial hypothalamic (VMH) areas, apparently by primarily targeting glucose-sensitive 
neurons74. The onset and extent of VMH lesions are dose-dependent and lesions become 
histologically obvious after 12 hours75. GTG-treated mice develop hyperphagia, in which 
glucose administration induces no satiety effect76. These mice are also characterized by 
increased body lipid and hepatic lipogenesis and triglyceride secretion as well as increased 
adipose tissue lipogenesis and decreased glucose metabolism in muscles.  These changes appear 
similarities to the later discussed genetically obese mice (ob/ob). Nevertheless, the main 
disadvantages include the long time-frame to develop obesity/diabetes and the exceptionally 
high rates of mortality after aurothioglucose injection69. The GTG mouse model is still used, 
for instance, to determine the mechanism of agents improving IR and preventing obesity77 and 
to learning the role of microRNA in insulin-resistant conditions, such as obesity or type 2 
diabetes mellitus 78. 
Other, less used, pharmacological agents for induction of obesity include 
cyproheptadine, a first generation antihistamine, clonidine, an adrenergic α2 receptor agonist, 
and chlordiazepoxide, a benzodiazepine 79.  
Important to note, there is a connection between the developmental exposure to a 
number of endocrine disrupting chemicals (EDCs) and diseases outcomes across the lifespan in 
animal models including obesity, TDM2 and fatty liver disease, thereby signifying the 
development of new biomarkers of exposure and disease outcomes as well as intervention and 
prevention studies 80. In this respect, the term “obesogen” refers to a chemical that could result 
in increased weight gain either directly through effects on fat cell development or indirectly 
through effects on other endocrine organs or the brain that could lead to augmented weight gain 
 
 
81. Currently, it is clear that T2DM and NAFLD can also be programmed in utero and early life 
by exposure to environmental chemicals in animal models 80,82,83. An examination of 
environmental chemicals that caused obesity, T2DM or fatty liver diseases showed that 
exposure to many of the same chemicals led to all three diseases. Besides, toxicology and 
epidemiology studies have suggested the involvement of diverse EDCs in an increasing number 
of metabolic disorders, including IR and IR-related co morbidities, such as obesity, T2DM, 
NAFLD and polycystic ovary syndrome, suggesting that EDCs could play an important role in 
the pathogenesis of these disorders 84. Thus, it has been proposed that they should be called 
metabolism disrupting chemicals (MDCs or metabolism disruptors) as they can lead to MetS. 
These include bisphenol A, DDT/DDE, tributyltin, smoking/nicotine, arsenic and it is likely 
this list will expand as more studies examine more endpoints related to metabolic diseases 80. 
The prevention of this field is an emerging area with enormous potential that only emerged in 
the last decade. There are a variety of approaches to mitigate or prevent these disorders from 
exposure to environmental chemicals.  
The advantages of pharmacological models include: i. they are comparatively cheaper, 
easier to develop and maintain. ii. selective loss of pancreatic β -cells with streptozotocin or 
alloxan leaves pancreatic α- and δ-cells intact. iii. Residual insulin secretion constitutes the 
rodents live long-term without being depended on insulin treatment and iv. Ketosis and 
resulting mortality are not common 69. Basic disadvantages of the pharmacological models 
include:  i.  possible toxicity at rest organs of the body. ii. Changes in P450 isozymes activity 
in the liver, kidney, lung, intestines, testis and brain have been reported after administration of 
alloxan or streptozotocin, which may affect the efficacy of the investigated medications, if they 
are metabolized at the same isoenzymes. iii. Study of diabetes is less optimal, since 





Surgical (mechanical) models of obesity 
This category consists one of the oldest being proposed for inducing rodent obesity and 
includes hypothalamic, ovarian and brown fat surgical interventions 41.   
 
Lesion of the ventromedial hypothalamus (VMH) 
Hypothalamic lesions were incriminated to induce obesity in the middle of 19th century 
86. The two widely used techniques to induce a VMH lesion in rats include the subcutaneous or 
intraperitoneal administration of monosodium glutamate (MSG) and electrical ablation 87.  
The most widely accepted mechanism of obesity via VMH lesions is the imbalance 
between sympathetic and parasympathetic stimulations 88–90. Vagal hyperactivity in VMH 
lesion models is associated with hyperinsulinemia, pancreatic islet cell hyperplasia, sensitive to 
streptozotocin and higher serum triglycerides 8,41,91. The plethora of receptors of weight 
regulating molecules, including leptin and melanocortin, in VMH and the comprehension of 
their pathophysiology tend to illuminate the exact effect of VMH lesions on obesity 91. Recent 
data indicate that carnitine palmitoyltransferase 1C (CPT1C), implicated in central regulation 
of energy, is essential for the activation of brown adipose tissue (BAT) thermogenesis driven 
by leptin, HFD exposure, and AMPK inhibition within the VMH, thereby underscoring the 
significance of uncoupling protein 1 (UCP1)C in the activation of BAT thermogenesis to 




Lesion of the hypothalamic paraventricular nucleus (PVN) 
  PVN is a key interface between the endocrine, autonomic and somatomotor systems that 
influence feeding behavior and energy metabolism 93. Food overconsumption and subsequent 
 
 
obesity of PVN lesion animal models follows the same pattern with the VMH lesions ones, 
however, lacks their manifestations 41,89. PVN neurons express a variety of weight modulating 
molecules and receptors 29,91. Maternal HFD during pregnancy and lactation seems to modify 
orexigenic mediators expressed by PVN neural cells in offsprings 29. 
Shi et al. suggested that PVN possesses an additional role to MetS, regulating the 
neurocircuitry of adipose afferent reflex in rats and subsequently the systematic blood pressure 
and hypertension 94. Moreover, recent data indicate that damage to Sim1 neurons (family BHLH 
Transcription Factor 1 (Sim1) neurons essential to control energy homeostasis) of the PVN is 
a shared feature of exposure to HFD in mice of both sexes 95; and caffeine, an antagonist of the 
adenosine receptor A1R, used as a dietary supplement to reduce body weight, reduces A1Rs 
expressed on PVN oxytocin neurons to negatively regulate energy balance in DIO mice  96.  
 
 
Lesion of the arcuate nucleus (ARC) 
Surgical demarcation of arcuate nucleus from the adjacent hypothalamic structures is 
not technically achievable 41. Ablation of ARC becomes possible using genetic or chemical 
methods (e.g. MSG or more selectively neuropeptide Y (NPY)-saporin injection) and abolishes 
the ARC-PVN neuronic axis 20,97,98. The clinical impact of that lesion concerns eating behavior 




The mentioned murine BAT located in the cervical–supraclavicular depot, plays a 
significant role on thermal energy production by expression of UCP1, which increases energy 
consumption in the mitochondria 99. BAT ablation is achieved in transgenic models when a 
UCP1-specific diphtheria toxin A is expressed 27,41,89,99. UCP1 deficiency reduces energy 
 
 
expenditure and results in obesity and IR, which worsen after HFD 27,41,89. In addition to UCP1 
deficiency, β3 adrenergic receptor (beta3-AR) under-expression in BAT is associated to obesity 
through decreasing energy consumption 100.  
 
Ovariectomy 
Ovariectomy has been established as the mainstay procedure to create gonadectomy 
models, resulting in estradiol insufficiency. The phenotypic changes include hyperphagia, 
weight gain and adipose mass increase 27,88. The exact pathophysiologic pathway after 
ovariectomy remains unclear; estrogen and leptin dysregulation has been underlined as the main 
mechanism, while a potential association of the role of NPY is also reported 87,101. Despite the 
aforementioned advantages, ovariectomy lacks the normal, gradual decrease of sex hormones 
during menopause and the physiologic compensatory responses 27,41. Additionally, lean mass 
in those rodent models is increased, unlike to human 102.  
 
Summarizing, surgical models of obesity are less used nowadays, since they expose 
animal to stress and pain, given that there are less technically demanding/invasive alternative 
ways to mimic human pathology 1. Moreover, mice are less appropriate due to their size 
(compared to other species) for the performance of operations 17. Additionally, targeted genetic 
disruption of concrete regions or cells in brain is generally favoured over the mechanical 
approach, since the latter influences not only all neurons in the targeted area, but also neuronal 





Genetic models of obesity 
Mouse models of monogenic obesity 
ob/ob mouse (Lepob//Lepob mouse or the “obese” mouse) 
The first and more representative genetic mouse model of a single spontaneous mutation 
is the so-called “obese” or ob/ob mouse, which arose in Jackson Laboratories in 1949, 
discovered by Coleman et al., and led later to the discovery of leptin 28,29,41. Leptin gene 
mutation (codon 105), which is seen in this model, is autosomal recessive (ob/ob) and is located 
on chromosome 6 and 7 in murine and human, respectively 27. The homozygous mutant mice 
are typically of C57BL/6J strain. This animal presents an early pronounced obese phenotype as 
a first feature, characterized by hyperleptinemia, hyperphagia, followed by hyperinsulinemia, 
IR, severe obesity, mild diabetes and fatty liver 41. However, unlike human obesity, ob/ob mice 
lack arterial hypertension and dyslipidemia even in the adolescence; on the contrary a HDL 
elevation has been described 27. The animal exhibits hepatic steatosis, but the progression to 
steatohepatitis (NASH) does not occur. For this, it is necessary the exposure of the mouse to a 
toxic agent, unlike humans, in which progression is a natural consequence of the disease 103. 
Additionally, these mice exhibit hypogonadism, hypothyroidism as well as GH insufficiency 
28. Interestingly, once the aforementioned leptin depletion is maintained on C57BL/KS strain, 
mice develop more severe diabetes with beta-cell complete loss and premature death 27,28. 
Besides, in both ob/ob and db/db mouse models, adiponectin homolog osmotin seems to 
protect obesity/diabetes-induced NAFLD via activation of adiponectin receptors (R1/R2) and 
its downstream APPL1/PPAR-α/AMPK/SIRT1 pathways. Therefore, it could be a potential 
novel therapeutic agent against obesity/diabetes-induced NAFLD and other MetS disorders; 
novel osmotin decreases body weight, blood glucose and glycated hemoglobin, IR and hepatic 
glycogenesis, improves glucose tolerance and increases fatty acid oxidation and mitochondrial 




db/db mouse (the ‘diabetic’ mouse) 
In accordance to “obese” mouse, the nonsense, spontaneous mutation of gene decoding 
leptin receptor (db/db) gave birth to the “diabetic” mouse 28,29. The gene is located on murine 
chromosome 4 27 and on human chromosome 1 105. The predominant mouse strain in which this 
mutation is maintained is the C57BL/KS. The phenotype is similar to that of ob/ob mouse 
regarding obesity, hypogonadism and GH insufficiency 27,28. However, more severe 
hyperglycemia and hyperinsulinemia are early (10th day) and progressively aggravate till 3 
months. Later on, insulin levels fall accompanied by β-cells atrophy. Endpoint is an average 
level of blood glucose >400 mg/dl (22.2 mmol/L), which contributes to an early death, before 
vascular and retinal diabetic complications are identified. Once the leptin receptor mutation is 
produced in a C57BL/6J strain, lifespan is not affected and diabetic symptoms are only mild, 
whereas obesity remains remarkable 28. Levels of leptin are increased due to the receptor 
mutation and subsequent leptin resistance. Thus exogenous administration of leptin, unlike to 
ob/ob mice, does not have any effect on weight reduction or other manifestations 41,90. Recent 
data indicate that, in db/db mice, platycodin D (active compound of root of Platycodon 
grandiflorum, which possesses anti-obesity actions) improves obesity by AMPK-related 
reduction of adipogenic markers such as PPARγ, and increases thermogenic factors, suggesting 
that its anti-adipogenic and thermogenic actions are dependent on the mentioned AMPK (AMP-
activated protein kinase) pathway activation 106; and the observed increased steroid hormone 
production and adrenal steroidogenesis in the db/db model of obesity and T2DM, signify 
that  steroid hormone dysfunction seems to be linked to obesity and T2DM development and 
correction of steroid abnormalities might offer new relative therapeutic approaches 107.  
 
s/s mouse 
This mutant mouse is also leptin receptor deficient, but arose as GEM and is regarded 
as more specific than the “diabetic” mouse. Instead of ubiquitous leptin receptor dysfunction, 
 
 
s/s mice are characterized by a mutation that disrupts the signal transducer and activator of 
transcription 3 (STAT3). They were developed by Bates at al. to clarify the role of individual 
leptin signals by provoking a knock-in mutation, which interrupted STAT3 pathway, a key 
molecule in intracellular leptin signaling 1,3,41. Similarly to db/db mice, this mutation results in 
leptin resistance and subsequent obesity and diabetes. Homozygous (s/s) mice are obese and 
hyperphagic, but maintain fertility, normal body length and develop less profound 
hyperglycaemia compared to their counterparts db/db, probably due to leptin action via other 
intracellular pathways 41. Energy restriction was able to normalize the glycemic control and IR 
in s/s mice 1. 
 
Lethal yellow mutant mouse (Ay) 
Agouti mutation mouse is one of the commonest and most successful models in obesity 
research. Although the mutation was known since the beginning of the last century, the model 
was created only in 1992. Agouti is a gene, responsible for controlling pigmentation and is 
expressed transiently in follicular melanocytes. It induces the production of yellow and red 
pheomelanin pigment with parallel inhibition of brown/black pigment 41,90,108. Production of 
pheomelanin is regulated through antagonism of α-melanocyte–stimulating hormone (MSH) on 
melanocortin-1 receptor during 4th to 6th day of murine hair cycle. The lethal yellow mutation 
(Ay) is one of the five known dominant agouti mutations and results in an ectopic expression of 
agouti. Mutant mice appear different and complex phenotypes with more representative the 
yellow coat coloration, mature onset of obesity, T2DM, IR, hyperleptinemia, tumor 
susceptibility, infertility and increased linear growth (compared to “obese” mouse). Of note, 
several transgenic Agouti mice have been generated; the selective cutaneous expression did not 
lead to obesity, suggesting that the obesogenic role of agouti is tissue dependent 41,90,108. 
Interestingly, in mice with the mentioned yellow mutation in the Agouti locus, metformin 
administration decreases body weight, restores the hypothalamic decreased activity of Akt 
 
 
kinase (key component of leptin pathway), and normalizes glucose tolerance and the 
hypothalamic increased subtype 1B serotonin receptor 109. Moreover, Ay mouse can serve as a 
novel and valuable preclinical model to investigate neurobehavioral complications correlated 
with obesity and T2DM 110. 
 
Fat (fat/fat or Cpe fat) mouse  
In 1973, another spontaneous gene mutation of inbred mice gave birth, manifesting 
obesity. Gene was named fat, its mutation was autosomal recessive and had no common 
components with db and ob genes. Later was demonstrated that mutation occurred within the 
gene of carboxypeptidase E (CPE) 111. CPE is a peptide-processing enzyme, involved in 
cleaving numerous peptide precursors, including neuropeptides and hormones participated in 
appetite control and glucose metabolism. For instance, CPE contributes to conversion of pro-
insulin to insulin in the periphery, and to cleavage of the pro-opiomelanocortine (POMC) in the 
CNS. Certain inactivating mutations of CPE result in inhibition of production of POMC 
derivatives, including α-MSH. It leads to to an imbalance between α-MSH and agouti-related 
protein activity at melanocortin receptors 3 and 4, thus promoting obesity 41.  
“Fat mice” have a later onset of obesity than “diabetic” and “obese” mice, averagely at 
six to eight weeks 41,111,112. By twelve weeks, the difference of body weight is profound, 
compared to wild-type littermates. A body weight of up to 70g can be seen in the first half year 
of life 111. Of note, wild-type adult mice weigh 20-40g 113. There are no observed gender 
differences in the rate of weight gain in mutant mice when compared to lean littermates. The 
excess weight in fat/fat mice is attributed to fat deposition to subcutaneous and visceral adipose 
tissue. Homozygous fat mutants become infertile, when obesity is established 41,111,112. Male 
and female fat/fat mice develop hyperinsulinemia; however, male experience a transient 
hyperglycemia between 6 and 8 weeks, whereas female remain normoglycemic. Of note, 
 
 
homozygous male mutant mice of C57BL/KS strain are particularly hyperglycemic, with 
reported blood glucose levels up to 600 mg/dL (33.3 mmol/L) 111. 
 
Tubby (tub/tub) mouse 
This mutation (tub) occurred spontaneously in a mouse of C57BL/6J genetic 
background 111. The expression of tub is primarily in the central and peripheral nervous systems, 
with very low expression also found in the liver 111. Its exact role remains largely unknown 41. 
Homozygous mutant mice develop a late-onset obesity that progresses even slower than the 
previous models. Moreover, they exhibit severe deafness and blindness. Increase of body 
weight, mainly attributed to adipose tissue deposition, can be seen at about 12 weeks and adult 
mice might double their body weight compared to lean littermates, although tubby mice are not 
particularly hyperphagic. They also develop IR and hyperinsulinemia 111. A mild 
hyperglycaemia can occur, but these mice do not develop typically an overt T2DM and they 
become infertile, when obesity is established 41,111. Interestingly at 7–8 weeks, orexin, NPY and 
agouti-related peptide are found to be upregulated in homozygotes. Metabolic defects become 
apparent even before the onset of obesity 111. Moreover, the occurrence of abnormal 
cholinergic/GABAergic vascular innervation in the ARC, indicates that alterations in this 
region, which includes neurons received information from the periphery and relays information 
about the energy status to other parts of the CNS, could be essential in the obese phenotype 
development in animals with an autosomal recessive mutation in the tub gene 114. 
 
Summarizing, monogenic models have the advantage of developing more severe obesity 
with distinct phenotypes, which facilitates mainly studies of medications, since their targets and 
effects are well characterized. In addition, they require shorter duration, because long feeding 
periods to induce obesity are not needed 115. Likewise, the genetic basis is homogeneous, the 
environmental factors are controlled, and the resulting variability is insignificant, thereby 
 
 
permitting the use of smaller samples 69. However, monogenic animals exhibit high mortality 
in certain strains, in addition to the necessity of sophisticated care of the animals, which makes 
the investigation more costly 69. Although monogenic models have been particularly useful in 
obesity investigation, the common underlying mechanisms between monogenic obesity in 
humans and several related pathologies remains poorly understood 116. Furthermore, monogenic 
obesity in humans represents only a small percentage, since common obesity in humans is 
mainly polygenic. Thus, the results of monogenic models may not be translated in the common 
human obesity.  
 
 
Mouse models of polygenic obesity 
 
New Zealand obese (NZO) mouse  
This model of polygenic obesity also demonstrates T2DM exclusively in male mice. 
The phenotype is impressive; adipose tissue early represents more than 40% of total body 
weight. Moreover, NZO mice show hyperphagia and decreased physical activity 108. Some of 
the implicated genes may be involved in the substrate utilization in the skeletal muscle and the 
triglyceride storage in adipocytes. Noteworthy, orthologs of at least some of these genes have 
been linked to human Mets 41. Recent data in NZO mouse indicate that MetS is associated with 
augmented mitochondria and peroxisomal activity to cope with dyslipidemia and 
hypercholesterinemia driven hepatic lipid overflow in fatty liver development 117; the cardiac 
phenotype in male NZO mice is connected with impaired cardiac energy function and signaling 
events 118. Etragonia tetragonoides (Pall.) Kuntze, called New Zealand spinach, used in salad 
in Western countries, exhibits anti-obesity, anti-lipidemic and anti-hyperuricemic actions in 
HFD-induced NZO mice, partially explained by regulation of lipid-metabolism-related genes 
and proteins and decreased expression of xanthine oxidoreductase. The expression and activity 
 
 
of the latter is associated with increased obesity and regulation of adipogenesis in adipose tissue 
119.  
 
Tsumura Suzuki obese diabetes (TSOD) mouse  
Tsumura and Suzuki developed two new inbred strains by using a selection of obese and 
urine sugar positive colonies from mice with ddY background. Only the males of these strains 
are characterized by obesity with hyperinsulinemia, hyperglycemia and T2DM. Although 
hyperglycemia progressively becomes severe, diabetes remains respectively mild, as mice have 
increased β-cell mass and maintain sufficient insulin secretion to control glucose [26]. Diabetic 
nephropathy and neuropathy can be seen to older mice 108. Interestingly, onset of NASH has 
been reported to TSOD mice and most of the older animals develop hepatocellular 
adenocarcinoma 120. In addition, femur bone mass is lower in TSOD mice since 
hyperinsulinemia during pre-diabetic and established diabetic conditions increases bone 
resorption due to high bone turnover 121.  
 
M16 Mouse 
M16 mouse was created on an ICR genetic background (named from the distributing 
Institute of Cancer Research) after tactful selection of mice, which achieved a weight gain in 3-
6 weeks; M16 mice is characterized as an outbred animal model to facilitate gene detection and 
pathway regulation monitoring early onset polygenic obesity and phenotypes of T2DM. 
Predominant phenotypes in this model, featuring obesity and diabesity, appear at a young age, 
thus closely mirroring current trends in human populations. They display, as compared to their 
wild-type littermates, hyperleptinemia, hyperinsulinemia and hyperphagia. Both sexes are also 





Kuo Kondo (KK) mouse  
Another polygenic model of obesity, which also demonstrates T2DM and was 
developed in Japan. Mice phenotype includes IR with accompanying hyperinsulinemia and 
hyperphagia as well as mild obesity at 2 months. Characteristic of this model is the late onset 
of obesity compared to the early onset of IR, implying that obesity is not the initial drive of IR. 
A variant of this model is the KKAy mouse, which was developed by transferring the mentioned 
lethal Ay gene (Ay) 108. 
 
Rat models of monogenic obesity 
 
The Zucker fatty rat (ZFR) 
Lois Zucker, through an experimental study, introduced a rat model in obesity research 
in 1961 122. The ZFR is characterized by homozygous mutation of a recessive gene (fa gene; 
fa/fa) 123 on chromosome 5 expressing leptin receptors; the mutated receptor, although 
expressed, remains mainly intracellularly causing a functional deficit 108,122. Primary obesity 
development at 3 weeks of life is the prominent phenotypic feature accompanied by secondary 
metabolic and hormonal deviations 41,108,122,124,125. This animal produces leptin, though there is 
no action of the hormone in its receptor, resulting in hyperphagia, with hyperleptinemia. Apart 
from leptin, additional orexigenic hormones are also high in this model 125. Adult ZFR exhibit 
40% of their weight in the form of fat and peripheral and liver IR, though glucose levels are 
normal, without development of T2DM 126. These findings resemble human exhibiting obesity 
and IR, but not T2DM  32. Hypoglucagonemia, dyslipidemia and hypertension are other 
components of MetS in ZFR 122,124,125,127–129. 
Sex hormones are also affected in both genders. Serum luteinizing hormone, follicle-
stimulating hormone, prolactin and progesterone fluctuation is impaired in female fa/fa rats, 
thus affecting fertility 130,131. Additional endocrine disorders, such as hypothyroidism and 
GH/insulin-like growth factor-1 (GH/IGF-1) axis disruption, are observed in all ZFR 41,89,132. 
 
 
Ιnterrupted glucose transportation seems to differentiate ZFR from a Zucker Diabetic Fatty rats 
(ZDF), thus predisposing to T2DM after HFD 41,68,89. Data indicate that IR and the resultant 
increased reactive oxygen species (ROS) impair functional dilation in ZFR, increasing 
thromboxane receptor-mediated vasoconstriction, whereas the reduction of IR and postprandial 
hyperglycemia significantly improves vascular OS and function 133,134  
 
Wistar fatty rat (WFR) 
In the early 1980s, coupling between Wistar Kyoto and Zucker fa/fa rats generated a 
monogenic leptin receptor depleted strain 135, which develops obesity and predisposes to MetS, 
IR, hyperinsulinemia, T2DM, hypertension and dyslipidemia (elevation of total cholesterol, 
low density lipoproteins cholesterol (LDL-C) and free fatty acids) 135,136. Metabolic outcomes 
are diet-induced and male rats are more vulnerable to these abnormalities. Diabetic neuropathy 
and nephropathy affect the elderly WFR, thus rendering them appropriate model for human 
T2DM 137,138. 
Additionally, studies of in utero HFD on WFR revealed genomic alterations in nucleic 
acids of hepatic cells and mitochondria affecting tissue IR and liver lipid profile 139–141. 
Interestingly, a low-protein diet seems to prevent diabetes progression in WFRs by reducing fat 
weight, increasing plasma fibroblast growth factor (FGF) 21 and high-molecular-weight 
(HMW) adiponectin levels, as well as UCP1 expression in the BAT, thereby leading to 
suppression of diabetic nephropathy 142.  
 
Koletsky rat (Obese Spontaneously Hypertensive Rat -SHROB) 
SHROB were generated after cross-fertilization between a spontaneously hypertensive 
(SHR) female rat and a male Sprague–Dawley rat 31,132. The prominent factor of obesity is a 
recessive mutation of leptin receptor gene (fak), causing a complete lack of the membrane-
bound segments of all gene isoforms in mentioned 111, in contrast to the functional disorder of 
 
 
leptin receptor in ZFR. Delayed weight gain begins after the 6th week, thus culminating at 750 
to 1000g 31,41,132. 
In addition to obesity, SHROB display IR combined with glucose intolerance, without 
T2DM development. Hypertension is more discrete than in ZFR and severe 
hypertriglyceridemia, mild hypercholesterolemia and NAFLD also occur. Abnormal protein 
excretion in urine after six months is early indicator of glomerulosclerosis and nephrosclerosis. 
These conditions are considered similar to human diabetic and hypertensive vasculopathy and 
nephropathy 31,41,132. With regard to reproductive ability, SHROB exhibit infertility with high 
testosterone in male rats and follicular atresia as wells as fewer corpora lutea in female ones 143. 
SHROB variants, such as obese homozygous (cp/cp) LA/N-cp and SHR/N-cp rats have been 
widely used in T2DM studies, reclaiming their metabolic similarities to human diabetic patients 
132. 
In view that prolactin-releasing peptide (PrRP) exhibits a potential to reduce food intake 
and improve obesity, recent data indicate that a new lipidized PrRP analog is efficient of 
improving glucose tolerance in obese SHROB rats by peripheral introduction, signifying that 
its effect on glucose metabolism is independent of leptin signaling and body weight lowering. 
Therefore this analog might be used as an agent with both anti-obesity and glucose-lowering 
properties 144.  
Short life expectancy (10–12 months), high development cost, the rarity of leptin 
receptor mutation in human and harsh management of these mutations in rodents constitute 
disadvantages not only for SHROB, but also for all leptin receptor-deficient rats 41,132. 
 
DS obese rat 
One of the most recently introduced rodent models for obesity, the DahlS.Z-
Leprfa/Leprfa rat strain, resulted after crossing the salt-sensitive Dahl rats and ZFR. Except for 
weight gain, additional features constitute DS obese rats suitable for MetS studies: visceral and 
 
 
subcutaneous adiposity, NAFLD, hypertension, elevated LDL-C to high density lipoprotein-
cholesterol (HDL-C) ratio, premature heart aging and diastolic impairment, renal dysfunction, 
and urine protein excretion 145,146. Interestingly, recent data indicate that the anti-inflammatory 
properties of atorvastatin on the cardiac and adipose tissues are attributable partially to the 
mentioned increased AMPK activity and decreased of nuclear factor NF-κB activity in DS 
obese rat model of MetS. 147. 
 
The GH-deficient dwarf (dw/dw) rat 
 
A spontaneous mutation of GH gene results in lower GH production and systematic 
release, thus provoking various manifestations. GH-deficient dwarf rats experience adipose 
tissue increase and impaired lipolysis. Some data indicate that the adiposity profile 
in dw/dw rats offers evidence of developmental abdominal leanness and hypoleptinemia in the 
context of profound GH deficiency. The underlying mechanisms of this puzzling leanness are 
yet to be recognized although do not seem to be the direct result of action in either GH signaling 
or energy intake. Identification of the genetic defect responsible for the dw/dw phenotype could 
discover a novel mechanism involving in the regulation of adiposity, and potentially new 
treatments. 148. 
 
Rat models of polygenic obesity 
 
Wistar Ottawa Karlsburg W (WOKW) Rat  
WOKW rat was generated by crossing outbred Wistar rat and BioBreeding diabetic rat, 
by inheriting RT1 haplotype of the major histocompatibility complex 132. The predominant 
manifestation of this inbred model is IR, in addition to obesity hyperlipidemia, hypertension, 
impaired glucose tolerance, hyperinsulinemia and enhanced autophagy in IR adipose tissue 149–
151. Specifically, up-regulated autophagy in obese WOKW rats contributes to the regulation of 
visceral adipose tissue function and involves a changed balance between pro-inflammatory and 
 
 
protective adipokine expression, thereby suggesting that adipose tissue autophagy activation 
seems to protect against adipocyte apoptosis under conditions of obesity-related MetS 
in WOKW rats; autophagy may act as a key protective rather than as destructive feature 152. 
Polygenic regulation of MetS in WOKW rats is considered as an advantage in MetS studies 
22,150. Moreover, elderly WOKW rats predisposed to coronary artery disease, thus reflecting 
human results of MetS 153. 
 
Sprague-Dawley rats 
Sprague-Dawley rats, in addition to Wistar rats, belong to the most commonly used rat 
models in diet surveys, as they offer easier manipulation and durability 31,38. These outbred 
rodents reflect the distribution of human population in obesity development; HFD provokes 
weight gain to many of these rats 3,29,41,112. Exhibition to high carbohydrate diets, such as 
fructose, could additionally cause hyperinsulinemia, hypertriglyceridemia, 
hypercholesterolemia, hypertension and IR 31. Recently, Ichimura et al. 154 showed that high fat 
and cholesterol diet induced NASH and hepatic fibrosis in Sprague-Dawley rats. Interestingly, 
DIO Sprague-Dawley rats display early post-weaning indicators of hippocampal inflammation, 
lipid peroxidation, reduced neural progenitor cell proliferation and defective hippocampal 
dependent memory by early adulthood, signifying that inherent metabolic alterations predispose 
this DIO strain to cognitive deficit prior to exposure to HFD and manifestation of obesity 155. 
In addition, maternal and post-weaning HFD settings could disturb hypothalamic neuronal 
signal irrelevantly, which is essential for leptin regulation of energy homeostasis and induce 
the risk of Sprague-Dawley rat offsprings to future metabolic disorders 156. Moreover, fecal 
microbiota transplantation appears to alleviate gut transit in the HFD-fed Sprague 
Dawley rats by regulating the serotonin biosynthesis, thus relieving gastrointestinal dysmotility 
(GID) and providing a perspective on the association between obesity and GID, as well as on 




Nile rat (African grass rat; Arvicanthis niloticus), Israeli sand rat (Psammomys obesus) 
Both Nile and Israeli sand rats were established for the purposes of MetS studies after feeding 
them with a chow diet. These wild rodents remain with normal weight in their natural habitat, 
whereas they develop obesity and T2DM in captivity - laboratory. Specifically, diabetes 
development and progression is very fast in the Israeli sand rats reaching the irreversible 
hypoinsulinemic disease stage, in which a marked reduction of β-cell mass is apparent, within 
4-6 weeks of high caloric diet 158. Metabolic disorders comprise hypertension, dyslipidemia, 
NAFLD and abdominal adiposity, thus resembling human obesity and glucose intolerance. The 
fundamental disimilarity is that the chow diet induces MetS, instead of high caloric input in 
human patients 68. 
 
The Otsuka Long-Evans Tokushima Fatty (OLETF) Rat  
OLETF rats resist to cholecystokinin peptide stimulus to food intake control, owing to 
the absence of its pancreatic receptor 30,132. An additional mechanism suggests the 
overexpression of NPY in the dorsomedial hypothalamus, thus inducing hyperphagia and 
impairing management of the energy balance 159. The phenotypic features of these models are 
hyperphagia, late onset obesity and T2DM (after 20 weeks), thus increasing weight by about 
1.5 times compared with the lean control and exhibiting glucose intolerance by week 24 68. 
Additional MetS components of these rodents are late onset hypertension, the isolated 
triglyceride increase, but for a slight elevation of serum cholesterol and NAFLD 68,132. OLEFT 
rats consist an important tool for studies of target-organ lesions due to MetS, as they manifest 
heart failure and glomerulosclerosis in adulthood 68. Nevertheless, weight loss was observed 
when OLETF rats access the running wheel and, depending on experimental conditions, weight 
preservation was achievable after exercise cessation. Current studies on OLETF target to 
illuminate NPY role and regulation, in order to clarify and suggest treatment options against 
 
 
obesity 101. Interestingly, cannabinoid 1 (CB1) receptor antagonist, rimonabant, seems to 
reverse NASH and its related features of MetS, by ameliorating hepatic fat infiltration, 
inflammation, cellular death and mRNA expression of proinflammation and fibrosis genes in a 
OLETF rat model of severely uncontrolled diabetes, implying the potential of pharmacological 
CB1 receptor blockade as a therapeutic regimen in the progression of NASH 160.  
 
One basic advantage of polygenic models as already discussed, is that they recapitulate better 
the human obesity and its energetic precursors. However its genetic basis is rather complex 
implicating many genes, rather than single gene mutations, which could simplify the research 
and reaching conclusions 1,3.   
 
Concluding remarks 
Τhe animal models can be considerably different from each other owing to the methods 
introduced to induce obesity. For instance, when compared with monogenic models, the DIO 
models could display less hyperphagia and several obese animal models do not exhibit 
increased fasting glucose levels and diabetes, despite similar levels of IR. Therefore, it is 
important to be aware of these characteristics when choosing obese animal model. Typical 
paradigms of potential non-specific impacts (such as hyperglycemia and hyperleptinemia) on 
innate immune responses from these different baseline parameters include the the fasting 
hyperglycemia in Zucker diabetic fatty rats vs. normal fasting glucose in obese Zucker rats, and 
the lack of leptin in ob/ob mice vs. high leptin in db/db mice. Likewise, investigators ought to 
be aware of the effect of aging on cardiovascular and immune systems in the obese animals 
models 161. Moreover, MetS parameters, including hyperlipidemia and hyperglycemia, 
frequently occur in obese models and seem to play an essential role in the development of 
chronic inflammation and CVD.  
 
 
Within this essay, we provided information regarding the most common mice and rat models 
of obesity and commented their advantages and limitations. Rodent models of obesity can 
recapitulate in a satisfactory manner the human pathology. The recent advantages in obesity 
pathophysiology can partly be attributed to the aforementioned preclinical studies with animal 
models. Although organoids become lately available and useful for tactfully chosen scientific 
questions, they are not able to fully replace the current cornerstone of basic research, namely 
mammalian models, since the latter better mimic the human, including physiology, nutrition, 
exercise, CNS control of obesity and body fat distribution. Moreover, it should be emphasized 
that a “wise” choice of the proper model of obesity would allow researchers reach validated 
and translational conclusions. Another substantial aspect is animal ethics and welfare, which 
should not be underestimated. Laboratory rodents are exposed to the chronic stress of 
manipulations and obesity with all their consequences and later on they are sacrificed. 
Principles which should be considered in experiments with laboratory animals include the so-
called 3Rs (replacement, reduction and refinement), originally introduced in 1959, with the later 
addition of 2Rs (robustness and reproducibility) 162. Wide-known guidelines which describe 
precisely how animal welfare is achieved and how stress is avoided are the ARRIVE ones 162. 
With these measures can humankind express its gratitude towards animals, which have largely 





Abbreviations: ARC; arcuate nucleus, BAT; brown adipose tissue, CPE; Carboxypeptidase E, 
DS; DahlS.Z-Leprfa/Leprfa, GH; growth hormone, HFD; high fat diet, HSD; high sugar diet, 
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Table. Features and metabolic components of Obesity rodent models 



















ob mutation + + + ± - - + 
db/db mouse  
db leptin receptor 
mutation 
+ + + + - + + 
s/s mouse STAT3 mutation + + ± - - - + 
Ay Lethal yellow mutant 
mouse  
Agouti mutation + + + + - + - 
fat/fat or Cpe fat mouse  
carboxypeptidase E 
mutation 
+ + + - - ± - 
Tubby mouse tub mutation - + + - - - - 
ZFR 
fa leptin receptor 
mutation 




+ + + + + + + 
Koletsky rat 
fak leptin receptor 
mutation 
+ + + - + + + 
DS obese rat 
Leprfa/Leprfa 
mutation 
+ + - - + + + 












New Zealand obese mouse male sex dependent + + + + + + - 
Tsumura Suzuki mouse  male sex dependent + + + + + + + 
M16 mouse ICR based mouse + + + - - - - 
KK mouse diet dependent + + + + - - - 
WOKW Rat  
RT1 haplotype 
inheritance 
+ + + - + + - 
Sprague Dawley rats diet dependent + + + - + + + 


























+ + + + + + - 




+ + ± - - - - 




+ - - - + + + 
ARC;  arcuate nucleus, BAT; brown adipose tissue, DS;  DahlS.Z‐Leprfa/Leprfa, GH; growth hormone, IR; insulin resistance, KK;  Kuo Kondo, NAFLD; 
nonalcoholic fatty liver disease, NPY; neuropeptide Y, OLETF; Otsuka Long-Evans Tokushima Fatty rats, PVN; paraventricular nucleus, STAT3; signal 
transducer and activator of transcription 3,T2DM; diabetes mellitus type 2, UCP1; uncoupling protein 1, VMH; ventromedial hypothalamus, WFR; Wistar 






Table 2. Basic features of obesity inducing diets 
 
Meal 
frequency Portion  Caloric source Limitations 
High Fat Diet 
(HFD) 
Normal Normal 45-60% animal fat 
High cost, model, age 
and sex dependent 
Cafeteria diets Increased Increased 
High fat and/or high sugar 
nutrition  
Difficult calculations of 
energy and 
macronutrient intake, 
lack of standarization 
Fat or sugar 
choice 
Increased Normal 
Free-choice of  “high-fat or high-
sugar” diet  
  
Meal feeding Unlimited Unlimited 
The most representantive: ad 
libitum model,offering to the 
subjects an unlimited access to a 
specific HFD 
Multi-variances 





Flavorful meals, “Rewarding” 
pattern 
Result based on rodent's 
susceptibility  
